Preclinical Research
Altasciences' Facilities: Moving in Unison
Ensuring Nonhuman Primate Availability for Your Studies
Altasciences Ensures Nonhuman Primate Availability
Several preclinical CROs are expecting an impact on study start dates due to nonhuman primate (NHP) supply constraints. NOT Altasciences. We ensure NHP availability! We have the capacity at our four preclinical sites to start your studies six to eight weeks following contracting, thanks to our steady supply of NHPs.
SCHEDULE YOUR NHP STUDIES TODAY!
At Altasciences, we remove the stress of sourcing research animals so that you can start your studies when you need to, with:
• dedicated and diversified cynomolgus monkey supply agreements in place to allow for faster start-up timelines;
• a continuously maintained and backfilled population of hundreds of naïve NHPs at our preclinical facilities.
You can schedule newly contracted NHP studies to start immediately.
Have five minutes? Discover our extensive site capabilities:
Webpage: Full Range of Preclinical Drug Development Solutions
Fact Sheet: Preclinical Services Capabilities
The Altascientist: Planning Your Preclinical Assessment
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
[NEW EBOOK] Safety Assessment for Ophthalmic Products
Excellence in Ophthalmic Safety Testing
Altasciences has been conducting ophthalmic safety testing for decades, with all global regulatory submissions from our studies approved for design, conduct, and data integrity. We perform ocular pharmacokinetic studies in multiple species (rodent and non-rodent), using different types of formulations and routes of administration, and support study durations ranging from single-dose acute to studies of six and nine months.
Learn more about our early phase ophthalmic drug development expertise in our latest eBook.
VIEW EBOOK
Do you have an ocular drug compound in your development pipeline?
Speak with one of our experts about your study or end-to-end, preclinical to clinical proof-of-concept program. Let’s get you started!
Related resources that may interest you:
The Altascientist: The Complexities of Early Phase Ophthalmic Drug Development
Fact Sheet: Comprehensive Services for Ophthalmic Drug Development
You have questions; we have answers.
| |||||||||||||||||||||||||||||||
|
To You, With Science - Our Latest Audiobook Releases
Listen to the Latest Audiobook Releases of The Altascientist
Delve deeper into the critical processes behind early phase drug development with audio versions of The Altascientist, written by our experts with you in mind:
Issue 31 — The Advantages of Conducting Early Phase Clinical Research in Canada | Issue 32 — A Changing Paradigm for Non-rodent Species in Nonclinical Safety Studies |
Issue 33 — CNS Drug Development: Integrated Solutions Lessen Complexity | In Case You Missed It: |
Miniature Swine: Changing the Bias for Nonclinical Studies on Small Molecules and Biologics
Miniature swine have been widely used for research studies since the 1960s—most commonly within the scope of dermal testing due to similarities of their integument to humans.
Safety Assessment for Ophthalmic Products